{"product_id":"sisram-medical-five-forces-analysis","title":"Sisram Medical Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDon't Miss the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSisram Medical faces moderate supplier leverage, intense competitive rivalry among device and service providers, and a rising threat from innovative substitutes and new entrants in aesthetic medicine, with buyer power amplified by channel consolidation and price sensitivity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized component dependency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSisram Medical depends on high-precision optical fibers, laser diodes, and specialized electronics for its energy-based devices; these parts are niche: about 70–80% of medical-grade laser sub-assemblies come from fewer than 10 certified global vendors as of 2025. \u003c\/p\u003e\n\u003cp\u003eBasic components are commoditized, but the limited supplier pool gives moderate bargaining power—supply disruptions could delay production and affect quality, risking revenue dips given 2024 device gross margins around 48%. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory compliance of the supply chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuppliers in the medical aesthetic industry must meet strict international standards like ISO 13485, which shrinks the supplier base and raises bargaining power for compliant vendors.\u003c\/p\u003e\n\u003cp\u003eFor Sisram Medical, this concentration means fewer alternatives and higher switching costs, pushing supplier leverage in pricing and lead times.\u003c\/p\u003e\n\u003cp\u003eBy end-2025, demand for sustainable, ethically sourced components—used in ~18–25% of device BOMs per recent industry surveys—further narrows viable partners, increasing their negotiation leverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegration with Fosun Pharma ecosystem\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs a Fosun Pharma subsidiary, Sisram Medical taps into the parent’s global procurement network—Fosun Pharma reported RMB 120.4 billion in 2024 revenue, boosting buying scale and supplier leverage. This scale cuts supplier power: bulk contracts and group-level framework agreements lower input costs and improve payment and lead-time terms. During 2020–2024 supply shocks, Fosun’s priority allocation helped Sisram maintain \u0026gt;95% fulfilment on key laser components. That priority and scale let Sisram secure preferential pricing and faster delivery.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSwitching costs for technical hardware\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe technical complexity of Sisram’s Alma devices makes switching suppliers for critical components costly: re-engineering and fresh regulatory filings (e.g., FDA 510(k) or EU MDR) can take 6–18 months and cost $0.5–$3M per device variant, giving existing suppliers measurable leverage.\u003c\/p\u003e\n\u003cp\u003eAs a result, Sisram favors multi-year, collaborative contracts with key tech partners, reducing supply disruption risk and capex for redesigns; long-term deals often cover 60–80% of critical-component spend.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e6–18 months typical re-certification delay\u003c\/li\u003e\n\u003cli\u003e$0.5–$3M estimated redesign\/regulatory cost\u003c\/li\u003e\n\u003cli\u003e60–80% of critical-component spend under long-term contracts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic concentration of raw materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe sourcing of rare earths and specialized minerals for Sisram Medical’s laser devices is heavily concentrated in Asia, notably China, which supplied about 60–70% of global rare earth oxides in 2024; that geographic concentration lets regional suppliers and policy shifts drive price and availability swings.\u003c\/p\u003e\n\u003cp\u003eSuppliers’ influence rose after China’s export quota changes in 2022–2023 and export duty guidance in 2024, so Sisram must hedge procurement and diversify contracts to keep cost of goods sold stable through end-2025 amid commodity volatility.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChina supplied ~65% of rare earth oxides in 2024\u003c\/li\u003e\n\u003cli\u003ePrice volatility: +22% peak-to-trough for key minerals in 2024\u003c\/li\u003e\n\u003cli\u003eMitigation: diversify suppliers, long-term contracts, strategic inventory\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier power high despite Fosun scale—supply concentration, switching costs risk COGS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold moderate-to-high power: 70–80% of laser sub-assemblies from \u0026lt;10 vendors (2025), China supplied ~65% of rare earths (2024), and device gross margin ~48% (2024), so disruptions raise COGS risk. Fosun scale (RMB 120.4bn revenue, 2024) cuts supplier power; long-term contracts cover 60–80% of critical spend, while switching costs (6–18 months, $0.5–$3M) maintain supplier leverage.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLaser vendors concentration\u003c\/td\u003e\n\u003ctd\u003e70–80% from \u0026lt;10\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare earths supply (China)\u003c\/td\u003e\n\u003ctd\u003e~65% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice gross margin\u003c\/td\u003e\n\u003ctd\u003e~48% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFosun Pharma revenue\u003c\/td\u003e\n\u003ctd\u003eRMB 120.4bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSwitching cost\u003c\/td\u003e\n\u003ctd\u003e6–18m; $0.5–$3M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLong-term contract coverage\u003c\/td\u003e\n\u003ctd\u003e60–80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Five Forces analysis for Sisram Medical that uncovers competitive intensity, buyer\/supplier power, threat of entrants and substitutes, and identifies disruptive trends and entry barriers affecting its profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise Porter's Five Forces snapshot for Sisram Medical—quickly spot competitive pressures and prioritize strategic moves.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh switching costs for practitioners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedical practices invest heavily in Sisram’s platforms—Soprano or Harmony—often spending $50k–$200k per device and 40–80 training hours per staff member, creating high switching costs. Once integrated, clinics face downtime, retraining, and capital write-offs, so switching to competitors is rarely economical. This lock-in lowers customer bargaining power and lets Sisram keep stable consumable margins (20–35% gross) and service fees. What this hides: small clinics still push back on bulk pricing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrand recognition and patient demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlma brand recognition drives patient demand: surveys show 48% of aesthetic patients in 2024 requested specific device brands, with Alma among the top three, pushing clinics to stock Sisram technology to stay competitive.\u003c\/p\u003e\n\u003cp\u003eBecause patients often choose treatments, clinics have reduced bargaining power; Sisram reported 2024 device revenues up 22%, indicating pricing resilience despite buyer concentration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFragmentation of the global clinic market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe majority of Sisram Medical’s customers are independent med spas, dermatologists, and small plastic surgery practices; this fragmentation means single buyers rarely exceed 1–2% of Sisram’s revenue, so they lack volume leverage to force discounts.\u003c\/p\u003e\n\u003cp\u003eLarge corporate aesthetic groups grew ~18% CAGR 2019–2024 but still account for under 20% of global clinic revenues, keeping pricing power with manufacturers like Sisram.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEssential nature of after-sales support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCustomers depend on Sisram for technical support, software updates, and proprietary consumables, creating high switching costs; in 2024 Sisram’s service revenue made up ~28% of medical segment sales, reinforcing recurring dependence.\u003c\/p\u003e\n\u003cp\u003eThis ongoing service tie shifts bargaining power to Sisram because clinics risk costly downtime—average device downtime loss ~USD 2,400\/day for aesthetic clinics—so they keep using certified parts and service.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eService revenue ~28% of medical sales (2024)\u003c\/li\u003e\n\u003cli\u003eAvg downtime cost ~USD 2,400\/day\u003c\/li\u003e\n\u003cli\u003eCertification required for warranty and compliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAccess to financing and leasing models\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBy 2025 Sisram Medical expanded flexible financing and leasing, cutting upfront costs and boosting device adoption by ~35% versus 2022, widening the practitioner pool but lowering buyer bargaining as clinics tie to Sisram’s contract terms.\u003c\/p\u003e\n\u003cp\u003eLeases commonly run 36–60 months and include service agreements that lock in maintenance revenue (estimated 20–30% of contract value), increasing vendor dependence and reducing customer exit options.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdoption +35% vs 2022\u003c\/li\u003e\n\u003cli\u003eTypical lease 36–60 months\u003c\/li\u003e\n\u003cli\u003eService revenue 20–30% of contracts\u003c\/li\u003e\n\u003cli\u003eHigher switching costs, lower buyer power\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSisram’s pricing power: high capex, costly downtime \u0026amp; recurring 20–35% consumable margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSisram faces low customer bargaining power: high device capex (USD 50k–200k), 40–80 training hours, service revenue ~28% of medical sales (2024), leases (36–60 months) boosted adoption +35% vs 2022, and avg downtime cost ~USD 2,400\/day—so clinics accept premiums and recurring consumable margins (20–35%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024\/2025)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice price\u003c\/td\u003e\n\u003ctd\u003eUSD 50k–200k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTraining\u003c\/td\u003e\n\u003ctd\u003e40–80 hours\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService rev\u003c\/td\u003e\n\u003ctd\u003e~28% medical sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdoption vs 2022\u003c\/td\u003e\n\u003ctd\u003e+35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLease term\u003c\/td\u003e\n\u003ctd\u003e36–60 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDowntime cost\u003c\/td\u003e\n\u003ctd\u003e~USD 2,400\/day\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumable margin\u003c\/td\u003e\n\u003ctd\u003e20–35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eSisram Medical Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Porter’s Five Forces analysis of Sisram Medical you'll receive upon purchase—no placeholders or mockups; the full, professionally formatted document is ready for immediate download and use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747574329721,"sku":"sisram-medical-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/sisram-medical-five-forces-analysis.png?v=1772200016","url":"https:\/\/matrixbcg.com\/products\/sisram-medical-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}